• Home
  • Sichuan Huiyu Pharmaceutical Co.,Ltd

Sichuan Huiyu Pharmaceutical Co.,Ltd

About Sichuan Huiyu Pharmaceutical Co.,Ltd

Huiyu pharm, founded in 2010, is a comprehensive pharmaceutical enterprise driven by research and development, mainly engaged in the research and development, production, and sales of anti-tumor injection.Also,it's dedicated to R&D and manufacturing of API products, with facilities approved by EU EDQM and China NMPA.Huiyu's products range from oncology,anti-infective to IDA, etc.

Read more Show less
Certifications
  • FDA
    FDA
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Middle East 2024

Riyadh Front Exhibition & Convention Center Riyadh, Saudi Arabia
10 Dec 2024 - 12 Dec 2024
View Exhibitor Profile

CPHI Frankfurt 2025

Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
View Exhibitor Profile

Products from Sichuan Huiyu Pharmaceutical Co.,Ltd (10)

  • Azacitidine Seacross 25mg/ml Powder for suspension for injection

    Product Azacitidine Seacross 25mg/ml Powder for suspension for injection

    Therapeutic indications:Azacitidine Seacross is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

    •intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System ...
  • Zoledronic Acid Seacross 5mg/100ml solution for infusion

    Product Zoledronic Acid Seacross 5mg/100ml solution for infusion

    Therapeutic indications:  
    Treatment of osteoporosis：•in post-menopausal women•in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy： •in post-menopausal wo...
  • Docetaxel 20 mg/ml Concentrate for solution for infusion

    Product Docetaxel 20 mg/ml Concentrate for solution for infusion

    Therapeutic indications:Breast cancer, sarcoma, small-cell carcinoma of the lung, Hodgkin disease or non-Hodgkin lymphoma, acute leukaemia, cancer of the thyroid, bladder, ovaries, Paediatric tumours, such as neuroblastoma. Doxorubicin is frequently used in combination chemotherapy regimens with other...
  • API: Carfilzomib/Bortezomib/Thiotepa/Ferric Carboxymaltose/Goserelin acetate/Ixazomib citrate

    Product API: Carfilzomib/Bortezomib/Thiotepa/Ferric Carboxymaltose/Goserelin acetate/Ixazomib citrate

    ——1. Carfilzomib: commercial API, DMF available, W.C. to be available in April 2024 2024)——Bortezomib: commercial API, DMF available, W.C. to be available in April 2024
    ——2. Thiotepa: 
    Commercial API, DMF available, W.C. to be available in April 2024
    ——3. Ferric carboxymaltose: ...
  • Paclitaxel 6 mg/ml concentrate for solution for infusion

    Product Paclitaxel 6 mg/ml concentrate for solution for infusion

    Paclitaxel Injection is used to treat:

    Ovarian cancer:

    • as first therapy (after initial surgery in combination with the platinum-containing medicine cisplatin).

    • after standard platinum-containing medicines have been tried but did not work.
    ...
  • Pemetrexed Seacross 100 mg / 500 mg powder for concentrate for solution for infusion

    Product Pemetrexed Seacross 100 mg / 500 mg powder for concentrate for solution for infusion

    Therapeutic indications: 

    • Malignant pleural mesothelioma

    in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.


    • Non-small cell lung cancer

    in c...
  • Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion

    Product Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion

    Irinotecan is indicated for the treatment of patients with advanced colorectal cancer:
    in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, as a single agent in patients who have failed an established 5-fluorouracil containing treatment regim...
  • Oxaliplatin 5mg/ml concentrate for solution for infusion

    Product Oxaliplatin 5mg/ml concentrate for solution for infusion

    Therapeutic indications: Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of primary tumour. Treatment of metastatic colorectal cancer.
  • Zoledronic acid 4 mg/5 ml concentrate for solution for infusion

    Product Zoledronic acid 4 mg/5 ml concentrate for solution for infusion

    Therapeutic indications:
    -To prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).


    -To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour. Tumours...
  • Docetaxel 20 mg/ml Concentrate for Solution for Infusion

    Product Docetaxel 20 mg/ml Concentrate for Solution for Infusion

    Docetaxel is used for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer.

    • For the treatment of advanced breast cancer, Docetaxel could be administered either alone or in combination with doxorub...